Invitae Corporation and Helix OpCo have announced a new partnership through which they plan to develop novel genetic testing applications to work with the latter’s CLIA-certified DNA sequencing platform.
The collaboration enables Invitae to offer some of the health apps on Helix’s platforms for common, actionable inherited disorders. The apps will provide healthy individuals / users a proactive genetic health scan mostly for inherited forms of cancer, cardiovascular disease, and other common diseases, for which preventative measure are available.
Invitae’s health scan apps on the Helix platform are anticipated to be available in 2017.
Zymo Research Corporation has received an exclusive license for a methylation age predictor, known as Horvath's Clock, named after its developer Dr. Steve Horvath, a professor at the David Geffen School of Medicine at University of California.
The Horvath Clock, which forms an important part of Zymo’s aging programme, uses DNA sample from any kind of biological source, except sperm, such as adipose tissue, bladder, blood and organs, to estimate the biological age of that tissue or cell.
The device can be effectively used for forensic, academic and consumer applications and also in a wide range of research such as cancer or stem cell.
FluoroPharma Medical has collaborated with Philips for image data management for Phase II clinical trial of its lead agent, CardioPET.
Phase II clinical study of CardioPET was conducted in Belgium and the data from the same was put through a rigorous quality assurance process with the help of Philips’ advanced molecular imaging systems available across clinical sites to ensure that consistent standards were vigilantly applied to data.
Medical diagnostics company, Breathtec BioMedical, intends to raise gross proceeds of up to C$1m ($0.76m) through a non-brokered private placement of approximately 13,333,333 units, with each unit containing one common share and one transferable common share purchase warrant exercisable into one additional share at a price of C$0.15 ($0.11).
The option is valid for three years from the closing date of the offering. The proceeds from the offering will be used by the company for general corporate purposes.
Global bioresource centre, ATCC, has initiated a strategic partnership with contract testing services provider, BioAgilytix, to develop new and custom cell-based assays that would help speed-up and improve the biopharmaceutical research and development.
Pursuant to the agreement the former will provide tool and reagent development and storage services, including custom-engineered cell lines and primary cells, while the latter provides broad array of assay solutions including those used to establish the potency and stability of therapeutic products.
Image: A man and a woman crouching. Photo: courtesy of Zymo Research Corp.